scholarly journals Carbohydrate 19.9 Antigen Serum Levels in Liver Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaetano Bertino ◽  
Annalisa Maria Ardiri ◽  
Giuseppe Stefano Calvagno ◽  
Giulia Malaguarnera ◽  
Donatella Interlandi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver ◽  
Neoplastic Disease ◽  
Prospective Longitudinal Study ◽  
Ca 19.9 ◽  
Prospective Longitudinal

Background.Carbohydrate 19.9 antigen (CA19.9) has been used in the diagnosis and followup of gastrointestinal tumours. The aim of this prospective longitudinal study was the evaluation of CA19.9 levels in patients with chronic hepatitis and hepatic cirrhosis hepatitis C virus and B virus correlated.Materials and Methods. 180 patients were enrolled, 116 with HCV-related chronic liver disease (48% chronic hepatitis, 52% cirrhosis) and 64 with HBV-related chronic liver disease (86% chronic hepatitis, 14% cirrhosis). Patients with high levels of CA19.9 underwent abdominal ecography, gastroendoscopy, colonoscopy, and abdominal CT scan.Results.51.7% of patients with HCV-related chronic liver disease and 48.4% of those with HBV-related chronic liver disease presented high levels of CA19.9. None was affected by pancreatic or intestinal neoplasia, cholestatic jaundice, or other diseases potentially able to induce Ca19.9 elevations. CA19.9 levels were elevated in 43.3% of HCV chronic hepatitis, in 56.3% of HCV cirrhosis, in 45.1% of HBV chronic hepatitis, and in 58% of HBV cirrhosis.Conclusions.CA19.9 commonly increases in the serum of patients with chronic viral hepatitis. Elevation of CA 19.9 is not specific for neoplastic disease and is related to the severity of fibrosis and to the viral aetiology of hepatitis.

scholarly journals Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review

2019 ◽  
Vol 57 (5) ◽  
pp. 577-610 ◽  
Author(s):  
Seyyed Mortaza Haghgoo ◽  
Heidar Sharafi ◽  
Seyed Moayed Alavian
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Growth Factor ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Chronic Liver ◽  
Major Health Problem ◽  
Non Invasive ◽  
Tgf Β1

AbstractChronic liver disease (CLD) is a major health problem worldwide. Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC), chronic hepatitis B (CHB), and alcoholic liver disease (ALD) are the most common etiologies of CLD. Liver biopsy is the gold standard for assessment of liver fibrosis, however, it is an invasive method. This review attempts to evaluate the usefulness of serum adiponectin, serum leptin, serum ferritin, serum transforming growth factor-β1 (TGF-β1), and serum platelet derived growth factor-BB (PDGF-BB) as non-invasive markers in the diagnosis of liver fibrosis/cirrhosis. A systematic search in MEDLINE, Web of Science, Scopus, and local databases was performed to identify articles published in English or Persian as of November 2017. Studies conducted among CLD patients, with biopsy proven fibrosis/cirrhosis, and providing sufficient details of patients’ clinicopathological characteristics were included. In the 95 studies included, there were a total of 15,548 CLD patients. More than 83% of studies were carried out in Asia and Europe. The relationship between liver fibrosis/cirrhosis and serum levels of ferritin, adiponectin, leptin, TGF-β1, and PDGF-BB was assessed in 42, 33, 27, nine, and three studies, respectively. Serum levels of the markers, particularly ferritin, could successfully predict liver fibrosis/cirrhosis, however, these data might not be clinically replicated and further studies are needed.

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

Blood ◽  
2010 ◽  
Vol 116 (16) ◽  
pp. 2875-2883 ◽  
Author(s):  
Vito Di Marco ◽  
Marcello Capra ◽  
Emanuele Angelucci ◽  
Caterina Borgna-Pignatti ◽  
Paul Telfer ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Chelation Therapy ◽  
Viral Infections ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical management of chronic liver disease in thalassemia patients is a team management issue requiring a multidisciplinary approach. The purposes of this paper are to summarize the knowledge on the epidemiology and the risks of transmission of viral infections, to analyze invasive and noninvasive methods for the diagnosis of chronic liver disease, to report the knowledge on clinical course of chronic viral hepatitis, and to suggest the management of antiviral therapy in thalassemia patients with chronic hepatitis B or C virus or cirrhosis.

scholarly journals Prevalence and Short Term Outcome of Spontaneous Bacterial Peritonitis of Known Chronic Liver Disease Patients

2015 ◽  
Vol 27 (1) ◽  
pp. 15-19 ◽  
Author(s):  
Mohammad Ismail ◽  
Mohammad Anisur Rahman
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Ascitic Fluid ◽  
Spontaneous Bacterial Peritonitis ◽  
Chronic Liver ◽  
Medical Emergency ◽  
P Value ◽  
Prospective Longitudinal Study ◽  
Bacterial Peritonitis ◽  
Prospective Longitudinal

Spontaneous bacterial peritonitis (SBP) is an infection of ascitic fluid occurring in the absence of a contiguous source of infection characterized by symptoms of fever, abdominal pain, rebound tenderness, encephalopathy. It may develope in hospitalized patients and mortality rate is significantly high. To determine the prevalence of SBP in chronic liver disease with ascites and to establish that SBP is the cause of higher mortality than non SBP, a prospective longitudinal study was carried out in patients attending in the inpatient Department of Gastroenterology of Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorder Hospital(BIRDEM), Bangabandhu Sheikh Mujib Medical University(BSMMU), Dhaka Medical College Hospital(DMCH), Dhaka from March 2010 to September 2010. Among the 60 patients the most common age group was the 46-55 years. In physical finding below average body build was found in 48 (80.0%) cases. Malnutrition was found in 48(80.0%) cases. Per abdominal finding liver was not palpable in 54 (90.0%) cases. Shifting dullness was found in 59 (98.3%) cases. Fluid thrill was detected in 57 (95.0%) cases. It was found that SBP were developed in 11(18.3%) cases and remaining 49(81.7%) case were non SBP, which were higher than SBP. Organism of culture of ascitic fluid in SBP patients (n=11) were E. coli and Pseudomoas spp found in 2(18.2%) cases, the rest 6(54.5%) cases shows no growth. Among 11 SBP patients improvement occurred in 5(45.5%) cases and the rest 6(54.5%) cases died p value <.001. SBP is medical emergency, prompt management and prophylactic antibiotics are essential to reduce mortality.Medicine Today 2015 Vol.27(1): 15-19

scholarly journals Serum levels of anti-heat shock protein 27 antibodies in patients with chronic liver disease

2020 ◽  
Vol 26 (1) ◽  
pp. 151-157
Author(s):  
Gabriella Gruden ◽  
Patrizia Carucci ◽  
Federica Barutta ◽  
Davina Burt ◽  
Arianna Ferro ◽  
...  
Keyword(s):  
Liver Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Chronic Liver

scholarly journals Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease

Hepatology ◽  
1997 ◽  
Vol 25 (5) ◽  
pp. 1271-1275 ◽  
Author(s):  
M W Fried ◽  
Y E Khudyakov ◽  
G A Smallwood ◽  
M Cong ◽  
B Nichols ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver ◽  
Hepatitis G Virus ◽  
Hepatitis G

Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C

2001 ◽  
Vol 195 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Mimoun Nejjari ◽  
Anne Couvelard ◽  
Jean-Fran�ois Mosnier ◽  
Alain Moreau ◽  
G�rard Feldmann ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver

scholarly journals Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

2020 ◽  
Vol 26 (2) ◽  
pp. 209-215 ◽  
Author(s):  
Seung Ha Park ◽  
Lindsay D. Plank ◽  
Ki Tae Suk ◽  
Yong Eun Park ◽  
Jin Lee ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Adult Population ◽  
Chronic Liver ◽  
Excessive Alcohol Consumption ◽  
Alcoholic Fatty Liver ◽  
Future Burden ◽  
Definition Of ◽  
Hepatic Steatosis Index

Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and 2016–2017. Data were extracted from the Korea National Health and Nutrition Examination Survey (1998–2001 to 2016–2017; n=25,893). Non-alcoholic fatty liver disease (NAFLD) was defined as a hepatic steatosis index >36 in the absence of any other evidence of CLD. The definition of alcoholrelated liver disease (ALD) was excessive alcohol consumption (≥210 g/week for men and ≥140 g/week for women) and an ALD/NAFLD index >0. The prevalence of NAFLD increased from 18.6% (95% confidence interval [CI], 17.8–19.5%) in 1998–2001 to 21.5% (95% CI, 20.6–22.6%) in 2016–2017. During the same time period, increases were observed in the prevalence of obesity (27.0 vs. 35.1%), central obesity (29.4 vs. 36.0%), diabetes (7.5 vs. 10.6%), and excessive drinking (7.3 vs. 10.5%). ALD prevalence also increased from 3.8% (95% CI, 3.4–4.2%) to 7.0% (95% CI, 6.4–7.6%). In contrast, chronic hepatitis B decreased from 5.1% (95% CI, 4.6–5.5%) to 3.4% (95% CI, 3.0–3.8%). The prevalence of chronic hepatitis C was approximately 0.3% in 2016–2017. The prevalence of NAFLD and ALD increase among Korean adults. Our results suggest potential targets for interventions to reduce the future burden of CLD.

Sign in / Sign up

Export Citation Format

Share Document